Table 1.
Patient characteristics
| Characteristics | Total (N = 162) |
|---|---|
| Age (years)a | |
| Mean (SD) | 65.3 (10.1) |
| Median (range) | 65.0 (38–90) |
| Female, n (%) | 100 (61.7) |
| Smoking status, n (%) | |
| Never | 92 (56.8) |
| Ever | 65 (40.1) |
| Unknown | 5 (3.1) |
| ECOG scoreb, n (%) | |
| 0 | 36 (22.2) |
| 1 | 108 (66.7) |
| 2 | 16 (9.9) |
| 3 | 2 (1.2) |
| Number of extrapulmonary sitesb | |
| Mean (SD) | 1.6 (1.0) |
| Range | 0–5 |
| Organs involved,b,c,d, n (%) | |
| Lymph node | 80 (49.4) |
| Bone | 65 (40.1) |
| Lung (other than primary) | 66 (40.7) |
| CNS i.e., brain, meninges, or spinal cord | 35 (21.6) |
| Charlson Comorbidity Index (CCI)e, n (%) | |
| Mean (SD) | 0.5 (0.8) |
| 0 | 97 (59.9) |
| 1–2 | 62 (38.3) |
| 3+ | 3 (1.9) |
| EGFR-mutation subtypec, n (%) | |
| Exon 19 deletionf | 92 (56.8) |
| Exon 21 L858R substitution | 61 (37.7) |
| Exon 20 T790M substitutionf | 2 (1.2) |
| Post-progression T790M resistance mutationc | 3 (1.9) |
| Otherf | 7 (4.3) |
CCI Charlson comorbidity index, CNS central nervous system, ECOG Eastern Cooperation Oncology Group, IQR interquartile range, mNSCLC metastatic non-small cell lung cancer, N total number of subjects, n number of subjects per category, SD standard deviation
aAt date of mNSCLC diagnosis
bAt the commencement of 1st line therapy for mNSCLC
cPercentages may add to more than 100% as patients may be counted in more than one category
dAmong those with extrapulmonary sites
eAll cancer-related conditions are excluded (leukaemia, lymphoma, any tumour, and metastatic solid tumour) in the CCI calculation
fSpecifically, 2 genetic mutations were detected in 3 patients. Each had an exon 19 deletion, 1 patient also had an Exon 20 T790M substitution and the other 2 patients had another genetic mutation